A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Brad S KahlMehdi HamadaniJohn RadfordCarmello Carlo-StellaPaolo CaimiErin ReidJay M FeingoldKirit M ArdeshnaMelhem SolhLeonard T HeffnerDavid UngarShui HeJoseph BoniKarin HavenithOwen A O'ConnorPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Loncastuximab tesirine had promising activity with acceptable safety in this dose-escalation study. A phase II study with initial dosing at 150 μg/kg has been initiated based on these results.